Literature DB >> 16632655

Nasal nitric oxide to diagnose primary ciliary dyskinesia in newborns.

F Stehling, C Roll, F Ratjen, H Grasemann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16632655      PMCID： PMC2672713          DOI： 10.1136/adc.2005.086702

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN： 1359-2998            Impact factor:   5.747


× No keyword cloud information.
  4 in total

Review 1.  Primary ciliary dyskinesia (PCD).

Authors:  M Meeks; A Bush
Journal:  Pediatr Pulmonol       Date:  2000-04

2.  Neonatal respiratory distress syndrome--a sign of primary ciliary dyskinesia?

Authors:  D Holzmann; H Felix
Journal:  Eur J Pediatr       Date:  2000-11       Impact factor: 3.183

3.  Nasal nitric oxide is low early in life: case study of two infants with primary ciliary dyskinesia.

Authors:  E Baraldi; M F Pasquale; A M Cangiotti; S Zanconato; F Zacchello
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

4.  Primary ciliary dyskinesia: age at diagnosis and symptom history.

Authors:  M E Coren; M Meeks; I Morrison; R M Buchdahl; A Bush
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299
  4 in total
  3 in total

1.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

Authors:  Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

2.  Feasibility of nasal NO screening in healthy newborns.

Authors:  Flurina Buechel; Jakob Usemann; A Aline; Peter Salfeld; Alexander Moeller; Andreas Jung
Journal:  Pediatr Pulmonol       Date:  2021-10-01

Review 3.  Genetic Testing in the Diagnosis of Primary Ciliary Dyskinesia: State-of-the-Art and Future Perspectives.

Authors:  Samuel A Collins; Woolf T Walker; Jane S Lucas
Journal:  J Clin Med       Date:  2014-05-09       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.